Assuming everything goes to plan, Ringel expects that Life Bio will enter clinical trials within a year with its ER-100 therapy, which leverages the expression of three transcription factors, Oct-4, Sox-2, and Klf-4 (OSK) to induce partial epigenetic reprogramming.
Sounds interesting. I wish the article included more details on how each of these transcription factors are thought to work.